Viatris Surges to 378th in Market Rankings with $279 Million Turnover

On May 8, 2025, Viatris (VTRS) saw a significant increase in trading volume, with a total turnover of $279 million, marking a 51.33% rise from the previous day. This surge placed Viatris at the 378th position in the day's stock market rankings. The stock price of Viatris rose by 5.70%, marking the second consecutive day of gains, with a total increase of 7.19% over the past two days.

Viatris reported its first-quarter 2025 financial results, revealing total revenues of $3.3 billion. This figure represents an 11% decrease on a reported basis and a 2% decline on a divestiture-adjusted operational basis compared to the same period last year. Despite the revenue shortfall, the company returned over $450 million to shareholders and reaffirmed its 2025 outlook.

Despite missing first-quarter estimates, Viatris maintained its full-year 2025 guidance. The company projected adjusted earnings per share (EPS) to range between $2.16 and $2.30, with revenue expected to fall between $13.5 billion and $14 billion. This guidance was further supported by positive data from two of its drugs, which contributed to the stock's upward movement.

Viatris also disclosed that it has raised its adjusted EPS outlook for fiscal 2025. The new projection ranges from $2.16 to $2.30 per share, up from the previous guidance of $2.12 to $2.26 per share. This adjustment reflects the company's confidence in its financial performance and future prospects.